Oculis Holding AG (OCS)
Oculis Holding AG at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Oculis Holding AG (OCS) is a Biotechnology company based in CH with a market capitalization of $683.7M. Free cash flow was negative at -$77.8M. This page tracks OCS's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
CH · 49 employees · IPO May 18, 2021
Valuation
Valuation & price
$30.29as of May 17, 2026· -7.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
3.48
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$683.7M
Market cap
—
Revenue growth (YoY)
-7492.3%
Gross margin
-$77.8M
Free cash flow (USD)
-$210.9M
Net debt
Net cash position
29.6%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2020 → 2025
Free cash flow by year
2020 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 6-K filed Jun 1, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
Questions
Frequently asked questions
What is Oculis Holding AG's market cap?
Oculis Holding AG (OCS) has a market capitalization of $683.7M.
What is OCS's P/E ratio?
A meaningful P/E ratio is not available for OCS — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is OCS's price-to-book (P/B) ratio?
OCS trades at 3.48 times book value per share.
Are insiders buying OCS stock?
SEC Form 4 filings show no open-market insider buys at Oculis Holding AG in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.